Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting

Summary

The experimental oral antiplatelet agent AZD6140 causes dyspnea in randomized trials. Whether clopidogrel may also cause dyspnea remains controversial. We sought to define the incidence and causes of dyspnea in a large post-percutaneous coronary intervention (PCI) cohort based on open-labeled consecutive registry analysis of in-hospital charts and discharge diagnoses. Data were collected at six-month follow-up by means of telephone interviews or returned questionnaires during outpatient visits. Patients undergoing coronary stent implantation were loaded with 600 mg clopidogrel followed by 75 mg/daily in combination with 75–325 mg of aspirin daily for at least six months. Data from 3,719 patients were analyzed. Dyspnea was diagnosed in 157 (4.2%) patients caused by chronic obstructive pulmonary disease (n=43 or 27% of the dyspnea group), heart failure (n=30 or 19%), cancer (n=22 or 14%), pneumonia (n=17 or 11%); asthma (n=8 or 5%), pulmonary hypertension (n=8 or 5%);pericarditis (n=5 or 3%);cardiac arrhythmias (n=4 or 2.5%); pleural effusion (n=1), pulmonary embolism (n=1), anxiety (n=1), or unknown (n=17,or 11%).The incidence of dyspnea at six months in a post-stent cohort treated with aspirin and clopidogrel is low (4.2%). The majority of patients with dyspnea (140/157) exhibit a distinct underlying disease or condition, in contrast to only 17 patients (0.45% of total cohort) in whom the pathogenesis of dyspnea remained unidentified. These data closely match the frequency of dyspnea that was observed in the CAPRIE trial, suggesting that therapy with clopidogrel, and/or aspirin holds very small (if any) risk for dyspnea.

Keywords

Aspirin - clopidogrel - registry - platelet inhibitors

• References

• 1 Serebruany VL, Stebbing J, Atar D. Dyspnea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract 2007; 61: 529-533.
• 2 Quan D, LoVecchio F, Clark B. et al. Prehospital use of aspirin rarely is associated with adverse events. Prehospital Disaster Med 2004; 19: 362-365.
• 3 Kurzyna M, Fijalkowska A, Kuca P. et al. Recombinant hirudine in suspected heparin induced throm-bocytopenia--case report of pulmonary embolism. Pol Arch Med 2000; 104: 785-789.
• 4 Coons JC, Barcelona RA, Freedy T. et al. Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother 2005; 39: 368-372.
• 5 Husted S, Emanuelsson H, Heptinstall S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6 140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047.
• 6 Cannon CP, Husted S, Harrington RA. et al. the DISPERSE-2 Investigators Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
• 7 Viegi G, Pistelli F, Sherrill DL. et al. Definition, epidemiology and natural history of COPD. Eur Respir J 2007; 30: 993-1013.
• 8 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
• 9 Plavix^® Package Inset. 2007
• 10 Uronis HE, Currow DC, Abernethy AP. Palliative management of refractory dyspnea in COPD. Int J Chron Obstruct Pulmon Dis 2006; 01: 289-304.
• 11 Pedersen F, Raymond I, Mehlsen J. et al. Prevalence of diastolic dysfunction as a possible cause of dyspnea in the elderly. Am J Med 2005; 118: 25-31.
• 12 Pedersen F, Mehlsen J, Raymond I. et al. Evaluation of dyspnoea in a sample of elderly subjects recruited from general practice. Int J Clin Pract 2007; 61: 1481-1491.
• 13 Witte KK, Clark AL. Why does chronic heart failure cause breathlessness and fatigue?. Prog Cardiovasc Dis 2007; 49: 366-384.
• 14 Temel JS, Pirl WF, Lynch TJ. Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 2006; 07: 241-249.
• 15 Testini M, Lissidini G, Gurrado A. et al. Acute airway failure secondary to thyroid metastasis from renal carcinoma. World J Surg Oncol 2008; 06: 14.
• 16 A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a study of PLATe let inhibition and patient Outcomes]. www.ClinTrials.gov Identifier NCT00391872
• 17 Basoglu OK, Pelleg A, Essilfie-Quaye S. et al. Effects of aerosolized adenosine 5'-triphosphate vs adenosine 5'-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma. Chest 2005; 128: 1905-1909.
• 18 Haskell CM, Mendoza E, Pisters KM. et al. Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 1998; 16: 81-85.